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ABSTRACT
Objectives To determine, in newborn infants referred
with elevated capillary thyroid-stimulating hormone
(TSH), a threshold below which a frankly subnormal
venous free thyroxine (fT4) level of <10 pmol/L is
unlikely, so that treatment with levo-thyroxine (L-T4)
might be deferred until venous thyroid function tests
(TFTs) become available.
Subjects and methods All infants referred in
Scotland since 1979 with capillary TSH elevation were
studied, with particular focus on infants screened using
the AutoDELFIA assay between 2002 and 2013.
Results Of the 321 infants referred with capillary TSH
elevation using AutoDELFIA, 35 were excluded (fT4/TSH
unavailable (12), venous sample either preceding or
>10 days after capillary sampling (13, 10)), leaving 286
eligible for analysis (208 deﬁnite/probable
hypothyroidism, 61 transient TSH elevation, 17 of
uncertain thyroid status). Capillary TSH and venous T4
were strongly correlated (Spearman’s rank correlation
coefﬁcient −0.707355). The optimal capillary TSH
threshold for predicting a venous fT4 of <10 pmol/L was
found to be >40 mU/L (90.3% sensitivity and 65.9%
speciﬁcity compared with 90.25% and 59.1% for
>35 mU/L and 88.3% and 68.2% for >45 mU/L). 93
infants (32.5%) had capillary TSH ≤40 mU/L at referral
of whom 15 (9.7%) had venous fT4 <10 pmol/L,
comprising seven with true congenital hypothyroidism,
ﬁve with transient TSH elevation and three with
uncertain status, two of whom died.
Conclusion For infants in whom capillary TSH is
≤40 mU/L, it is reasonable to defer L-T4 treatment until
venous TFT results are known provided that the latter
become available quickly.
INTRODUCTION
Congenital hypothyroidism, the most common
paediatric endocrine disorder, is very important
clinically since severe cases will lead to irreversible
mental handicap without prompt treatment.1 The
reported incidence varies according to whether or
not newborn screening is practised and if so by the
cut-off used by the referring laboratory in terms of
capillary thyroid-stimulating hormone (TSH) and
thyroxine (T4). For example in Canada, where a
capillary TSH threshold of 15 mU/L is used, the
incidence of congenital hypothyroidism is 1 in
2600 births.2 Although capillary TSH screening for
primary congenital hypothyroidism, which began
in Scotland in 1979,3 has revolutionised the neuro-
logical outcome, some early treated infants still
demonstrate a range of problems including subtle
impairment of cognition, attention and memory
deﬁcit and vestibuloauditory problems,4–6 espe-
cially when postnatal care has been inadequate.6
Prompt treatment with levo-thyroxine (L-T4) of
severe cases is therefore highly desirable.
When a newborn infant is referred with capillary
TSH elevation, the physician needs to distinguish
between congenital hypothyroidism requiring
immediate treatment and milder thyroid dysfunc-
tion which may resolve without treatment.
Following clinical assessment, a good venous blood
sample for measurement of free thyroxine (fT4)
and TSH is mandatory, since the result reﬂects the
presence and severity of congenital hypothyroid-
ism.7 However, at initial evaluation, only the capil-
lary TSH value is available, and it may not be
possible in all centres and in all countries to have
the results of venous blood tests on the same day.
The crucial component of the venous blood
sample is the T4 level, usually measured as fT4.
Work of Mutlu et al8 in 296 newborns showed that
on day 10 the 2.5th centile, 50th centile and
97.5th centiles for fT4 were 15.2, 22.5 and
32 pmol/L, respectively. It was on this basis that the
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What is already known on this topic
▸ Most newborn infants referred with capillary
thyroid-stimulating hormone (TSH) elevation on
newborn screening have congenital
hypothyroidism requiring treatment with
levo-thyroxine (L-T4).
▸ Some infants with capillary TSH elevation are
found not to have congenital hypothyroidism
so that treatment can either not be started or
be discontinued.
What this study adds
▸ Infants in whom capillary TSH is ≤40 mU/L
have a low probability (10%) of having a
subnormal venous free thyroxine level of
<10 pmol/L.
▸ It is reasonable to defer L-T4 treatment in such
infants until the results of venous thyroid
function tests become available.
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European Society for Paediatric Endocrinology consensus group
on congenital hypothyroidism deﬁned the severity of hypothy-
roidism in terms of fT4 ranges, with <5 pmol/L as severe, 5–
10 pmol/L as moderate and 10–15 pmol/L as mild
hypothyroidism.7
When capillary TSH is grossly elevated, for example,
>100 mU/L, with or without clinical features of hypothyroid-
ism, the clinician will wish to start L-T4 treatment immediately
since moderate or severe hypothyroidism is likely. The decision
is less clear in an asymptomatic newborn with modest capillary
TSH elevation, for example, 15–40 mU/L, where venous fT4 is
unlikely to be frankly low, and more likely to be either mildly
subnormal (10 to <15 pmol/L) or within the newborn reference
range of 15–32 pmol/L. When the results of venous thyroid
function tests (TFTs) will be available on the same day as vene-
puncture, the clinician can be guided by the fT4 levels.
Although this same-day service will be routinely provided now-
adays by laboratories in developed countries, the availability of
venous results may still be problematic outside normal working
hours and at weekends. Moreover, a same-day service may not
be feasible in many countries with limited resources. In such
situations, the clinician faces the dilemma as to whether to treat
immediately or whether to await the venous results before com-
mitting the infant to several years of treatment with L-T4.
To date the relationship between capillary TSH levels mea-
sured in the course of newborn screening and serum thyroid
hormone levels has not been explored. In this study, data from
all infants referred by the Scottish Newborn Screening
Programme with capillary TSH elevation has been reviewed
with particular focus on infants evaluated by the AutoDELFIA
assay since 2002. The aim is to determine a capillary TSH
threshold below which decompensated primary hypothyroidism
is unlikely so that immediate treatment with L-T4 is not indi-
cated and can be deferred until venous TFT results become
available.
PATIENTS AND METHODS
Since 1990, a computerised database has been kept of all infants
referred by the newborn screening laboratory in Scotland since
August 1979.3 9 This database records capillary TSH values (one,
two or three samples depending on whether or not the labora-
tory have requested repeat tests) and venous total (t) T4 in nmol/
L (prior to 1996) and venous fT4 in pmol/L thereafter measured
on the ﬁrst assessment sample prior to starting LT-4 replacement.
Patients were classiﬁed as having deﬁnite congenital hypothy-
roidism, probable congenital hypothyroidism, transient TSH
elevation and status uncertain, as previously described.3 9 The
deﬁnitions for these four categories take into account the fact
that thyroid imaging has not been consistently carried out in all
Scottish centres since screening began, although combined
radioisotope and ultrasound scanning has become the norm in
the West of Scotland since 1996.10
Analysis of capillary TSH and venous fT4 and tT4 data was
carried out in relation to the four time periods during the study
in which the assay and hence the normal, recall range and
immediate referral cut-offs (mU/L) differed. These were:
▸ 1979–1982—Corning TSH radioimmunoassay (RIA): <25,
25–49, >50
▸ 1982–1989—in-house TSH RIA: <15, 15–39, >40
▸ 1989–2002—ImmunoDiagnosticsSystems TSH immunora-
diometric assay (IRMA): <10, 10–39, >40
▸ 2002–present—Perkin-Elmer TSH dissociation-enhanced lan-
thanide ﬂuorescence immunoassay (DELFIA): <8, 8–24,
>25
The entire cohort of patients from the 34-year period
between August 1979 and December 2013 in whom both capil-
lary and venous TSH data were available was analysed, followed
by more detailed analysis of patients screened by
the AutoDELFIA method from 2002 onwards. Total thyroxine
values were converted to fT4 using an approximate in-house
conversion division factor of 7.25.11 Where there were two
samples from the same day, the second sample value was taken.
Data were excluded when venous testing took place more than
10 days after the initial capillary sample test. In cases where the
date of venous sampling was missing, it was calculated as age at
notiﬁcation plus 1 day, based on Scottish data showing that
median age at notiﬁcation and start of treatment were 12 versus
13.5 days in 344 patients from 1979 to 1993 and 10 versus
11 days in 250 patients from 1994 to 2003, indicating an
approximate 1 day difference.9
Statistical analysis
The Shapiro–Wilk W test was initially used to test data for nor-
mality and indicated a non-normal distribution; therefore, non-
parametric tests were used for data analysis, values being
expressed as median with either range or IQR. Correlation
between venous fT4 and capillary TSH were analysed using
Spearman’s rank correlation test and expressed as a coefﬁcient
of correlation with CIs. Receiver-operating characteristic (ROC)
curve analysis was performed to explore the relationship
between selected capillary TSH cut-offs and pretreatment
venous fT4 levels, estimating the sensitivity and speciﬁcity at dif-
ferent capillary TSH cut-offs in predicting venous frank hypo-
thyroidism, deﬁned as fT4 <10 pmol/L. The optimal capillary
TSH threshold was identiﬁed as that which had the highest spe-
ciﬁcity in association with a sensitivity approaching 90%.
Venous fT4 data according to selected capillary TSH ranges
were also expressed as ‘box and whisker’ plots using StatsDirect
software (Altrincham, Cheshire, UK).
Ethical aspects
The Glasgow West Research Ethics Committee has previously
approved data extraction from our database for audit and
re-evaluation, provided that the data are anonymised. Since
2002, parents have given informed consent for data storage and
for later anonymised data analysis and presentation. This project
was registered with the Clinical Governance Support Unit of
NHS Greater Glasgow and Clyde as a Quality Improvement
Project.
RESULTS
General information
Between August 1979 and December 2013, 793 infants were
referred by the screening laboratory and their outcome is shown
in ﬁgure 1. Deﬁnite hypothyroidism was conﬁrmed in 564
infants with probable hypothyroidism in 16, transient TSH ele-
vation in 181 and status still uncertain in 32. Of the 564 infants
with true congenital hypothyroidism 177 (31.3%) underwent a
second capillary sample, while 7 (1.2%) underwent a third
capillary sample. Recall rates were higher for the 181 infants
with transient TSH elevation, 88 (48.6%) of whom required a
second sample and 17 (9.4%) a third sample. Age at venepunc-
ture was missing in 23 of the 793 infants (9 with deﬁnite and
one with probable congenital hypothyroidism, one with status
uncertain and 12 with transient TSH elevation) so that this was
derived from age at notiﬁcation as described above.
Median (IQR) age at ﬁrst capillary TSH testing was 6 days
(5–7 days) for all infants and 6 days (5–7 days) after excluding
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infants with transient TSH elevation and status uncertain.
A second capillary test was required in 177 infants, median
(IQR) age at testing 16 days (13–21 days). For infants subse-
quently diagnosed with deﬁnite or probable hypothyroidism,
median age at second testing was 15 days (12.5–19 days).
A third capillary test was required in 27 infants, median (IQR)
age 27 days (22–33.5 days). Of these, seven were diagnosed
with deﬁnite hypothyroidism, median (IQR) age at third testing
24 days (22–31 days).
Analysis of cohort from 2002 onwards using the AutoDELFIA
assay
Between January 2002 and December 2013, a total of 321
infants were referred by the Scottish Newborn Screening labora-
tory using the same AutoDELFIA assay. Thirty-ﬁve were
excluded from analysis due to the age at venous sample
>10 days after the capillary test (10 infants), venous TSH or
fT4/tT4 unavailable (12 infants) and venous sample taken prior
to ﬁrst capillary sample (13 infants). This left 286 infants who
met our criteria for analysis: 208 with deﬁnite and probable
hypothyroidism, 61 with transient TSH elevation and 17 of
uncertain thyroid status. Age at venepuncture was missing and
hence derived from notiﬁcation in one infant with deﬁnite con-
genital hypothyroidism and two with transient TSH elevation.
Correlation between capillary TSH and venous fT4 testing
There was a strong correlation between capillary TSH at screen-
ing and conﬁrmatory venous fT4 testing following referral with
a highly signiﬁcant Spearman’s rank correlation coefﬁcient of
−0.707355 (p<0.0001, 95% CI after using Fisher’s Z trans-
formed −0.760912 to −0.644225).
Sensitivity and speciﬁcity of different capillary TSH cut-off levels in
predicting low venous fT4
Table 1 and ﬁgure 2 show that a cut-off value of >40 mU/L for
capillary TSH gives a 90.3% sensitivity (95% CI 84.4 to 94.4)
and a 65.9% speciﬁcity (95% CI 57.2 to 73.9) for predicting a
venous fT4 value of <10 pmol/L, which would indicate the
need for treatment with L-T4. Therefore, a capillary TSH
cut-off of >40 mU/L would detect 90.3% of those infants with
frankly low venous fT4, while 65.9% of infants with fT4
>10 pmol/L would have capillary TSH values of ≤40 mU/L.
Figure 1 Consort diagram showing outcome in 793 infants referred
with capillary thyroid-stimulating hormone (TSH) elevation by the
Scottish Newborn Screening laboratory between August 1979 and
December 2013. Note that the infants who had two capillary screening
samples performed (middle large box) are also included in the upper
box since all infants had one sample taken. Those infants who had
three capillary samples performed (lower large box) are included in
both preceding boxes.
Table 1 Sensitivity and specificity of different capillary TSH cut-off
levels in predicting a venous fT4 of <10 pmol/L in 286 Scottish
infants referred with capillary TSH elevation
Capillary TSH cut-off
(mU/L whole blood) Sensitivity Specificity
>10 0.987013 0.106061
>20 0.961039 0.356061
>30 0.922078 0.537879
>35 0.902597 0.590909
>40 0.902597 0.659091
>45 0.883117 0.681818
>50 0.857143 0.719697
>60 0.831169 0.795455
>70 0.818182 0.848485
>80 0.792208 0.878788
>90 0.75974 0.886364
>100 0.746753 0.901515
>110 0.74026 0.939394
>120 0.694805 0.954545
Sensitivity refers to the proportion of infants with fT4 of <10 pmol/L whose capillary
TSH is above a given cut-off value, while specificity refers to the proportion of infants
with fT4 ≥10 pmol/L whose capillary TSH is below the cut-off value. fT4, free
thyroxine; TSH, thyroid-stimulating hormone.
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Moreover, the area under the ROC curve is 0.89 (95% CI 0.86
to 0.93), indicating that referral capillary TSH is a strong pre-
dictor of subsequent fT4 values. A capillary TSH threshold of
>35 mU/L has almost identical sensitivity but lower speciﬁcity
(59.1%), while sensitivity is lower (88.3%) for a cut-off of
>45 mU/L and speciﬁcity is lower (53.8%) for a cut-off of
>30 mU/L compared with the >40 mU/L cut-off.
Of the 286 infants analysed, 93 (32.5%) had capillary TSH
values of ≤40 mU/L at referral comprising 32 (11.1%) with
TSH 25–40 mU/L at ﬁrst testing and immediate referral; 57
(19.9%) with TSH 8 to ≤25 mU/L on ﬁrst sample and
8–40 mU/L at second sample prior to referral and 4 with TSH
8–40 mU/L on third sample.
Comparison between 1979–2001 and 2002–2013 data
Data from 1979 to 2001 showed higher sensitivity (96.4% vs
90.3%) but much lower speciﬁcity (22.6% vs 65.9%) for
Figure 2 Receiver-operating
characteristic curve analysis of capillary
thyroid-stimulating hormone (TSH)
levels predicting a venous free T4
value of ≤10 pmol/L in 286 newborn
infants with TSH elevation on newborn
screening.
Figure 3 Median (range) venous free
T4 according to range of capillary
thyroid-stimulating hormone (TSH) in
286 infants with raised TSH on
newborn screening.
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Table 2 Data on 15 infants referred with elevated capillary TSH in whom capillary TSH was <40 mU/L and venous fT4 was <10 pmol/L
Patient
no.
BW
(kg)
GA
(weeks)
Sick?
(Y/N)
cTSH (mU/L) (age
in days)
vTSH (mIU/L)
(age in days)
vfT4
(pmol/L) Comment
First cTSH (mU/L)
(age in days)
Other cTSH (mU/L)
(age in days)
True congenital hypothyroidism
1 2.95 39 N 9.5* (12) 22.7 (18) 4.8 Probable dyshormonogenesis on radio-isotope scan 23.2 (5)
2 4.22 42 N 21.8* (17) 49.9 (20) 8.0 Confirmed CH (rising TSH on diagnostic challenge) but no imaging performed 9.42 (5)
3 3.54 39 N 25.7 (6) 55.0 (15) 9.0 Dyshormonogenesis (no mutation found)
4 2.8 40 N 26.4* (18) N/A (22) 7.1 Dyshormonogenesis; IUGR 15.3 (6)
5 3.08 38 N 14.3* (15) 52.45 (24) 6.6 Confirmed CH but cause unknown (no uptake on RIS but on L-T4 for > 4 weeks
prior to imaging)
13.7 (6)
6 3.52 40 N 34.9* (14) >100 (16) 6.0 Dyshormonogenesis (confirmed TPO defect) 10.16 (5)
7 1.66 28 Y 32.3 (4) 27.0 (9) 7.5 Respiratory distress syndrome with small IVH in perinatal period). Confirmed CH
(TSH 15.9 mU/L after >1 year on L-T4 therapy)
Status uncertain
8 3.5 39 Y 15.0† (25) 11.2 (29) 6.6 Interrupted aortic arch and Di George (died aged 3 months) 10 (6) 20 (16)
9 1.04 29 Y 21.0* (15) 41.8 (17) 7.2 Down syndrome with AVSD and chronic lung disease (died aged 6 months) 7.4 (6) 75 (23) NB after vTFTs
10 1.49 31 N 21.0* (10) 150 (15) <5.0 PDA (resolved). No imaging performed. Still on L-T4 5.77 (5) 48.4 (17) NB after
vTFTs
Transient TSH elevation
11 3.83 40 N 27.0* (27) N/A (36) 9.7 No imaging; treatment never started 16 (4)
12 2.9 37 Y 15.0* (18) 110 (24) 4.8 ECMO for Group B Streptococcus sepsis 14 (14)
13 3.65 37 N 33.0* (18) 75.0 (22) 9.8 PAX8 mutation and thyrotropin receptor polymorphism 9 (6)
14 3.01 37 Y 9.8 (10) 73.5 (17) 5.1 Renal and lung dysplasia, imperforate anus 182.03 (39) NB after
vTFTs
15 1.01 27 Y 11.2† (28) 17.9 (36) 9.4 Preterm/VLBW 1.49 (5) at 28 weeks
GA
11.8 (25)
*Repeat sample.†Second repeat sample.
AVSD, atrioventricular septal defect; BW, birthweight; CH, congenital hypothyroidism; cTSH, capillary thyroid-stimulating hormone; ECMO, extra-corporeal membrane oxygenation; fT4, free thyroxine; GA, gestational age; IUGR, intrauterine growth
restriction; IVH, intraventricular haemorrhage; L-T4, levo-thyroxine; N/A, not available; NB, nota bene; PDA, patent ductus arteriosus; TPO, thyroperoxidase; TSH, thyroid-stimulating hormone; vfT4, venous free thyroxine; VLBW, very low birth weight; vTFT,
venous thyroid function test.
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detecting venous fT4 <10 pmol/L with a capillary TSH cut-off
of >40 mU/L (area under the ROC curve 0.83494).
Venous fT4 levels according to capillary TSH cut-off in
infants screened between 2002 and 2013 using the
AutoDELFIA method
Figure 3 shows a box and whisker plot of fT4 values grouped
according to capillary TSH ranges. Median venous fT4 was
15 pmol/L for capillary TSH values of between 0 and 20 mU/L
(n=53). Median fT4 was also 15 pmol/L for capillary TSH
values of 20–40 mU/L (n=48); 11 for values of 40–60 mU/L
(n=28); 11 for values of 60–80 mU/L (n=19) and 5 pmol/L
when capillary TSH was >80 mU/L (n=138).
ANALYSIS OF PATIENTS SCREENED BETWEEN 2002 AND
2013 WITH VENOUS FT4 <10 PMOL/L IN WHOM CAPILLARY
TSH WAS ≤40 MU/L
Of the 154 patients with frankly subnormal fT4 of <10 pmol/L,
15 (9.7%) had capillary TSH values at the time of referral of
<40 mU/L and their details are given in table 2. All but three
had been referred after a repeat capillary TSH had been
requested, and two infants (patients 8 and 15) were referred
after the second repeat. Seven infants were found to have true
hypothyroidism, ﬁve had transient TSH elevation and status was
uncertain in three patients, of whom two died. Although venous
TSH was higher than capillary TSH (consistent with assay dif-
ferences and also with a rise having occurred between capillary
and venous sampling), the degree of elevation was modest in
relation to the venous fT4 being <10 pmol/L. Thus, venous
TSH was <30 mU/L in four patients (patients 1, 7, 8, 15) and
only 30–60 mU/L in a further four patients (patients 2, 3, 5, 9).
Moreover, fT4 was severely reduced at <5 pmol/L in three of
the patients (patients 1, 10, 12).
DISCUSSION
This study shows that even when capillary TSH is only just above
the Scottish threshold for referral (≥8 mU/L), there is a risk that
venous thyroid hormones will be low. This was the case in 15
infants who were found to have frankly low venous fT4
(<10 pmol/L) on initial venous sampling despite only mild capil-
lary TSH elevation, ranging between 9.5 and 34.9 mU/L. Thus,
two infants with subnormal fT4 (patients 1 and 14 in table 2) had
capillary TSH values of <10 mU/L, while three (patients 8, 12
and 15) had values between 10 and 20 mU/L and two (patients 9
and 10) had values between 20 and 25 mU/L. These ﬁndings are
in keeping with work from Italy showing that capillary TSH
cut-offs of 10 and 12 mU/L were superior to 20 mU/L in detecting
thyroid dysgenesis.12 It follows that infants referred with capillary
TSH elevation values just above the national or regional screening
threshold should be investigated promptly, since true congenital
hypothyroidism may be discovered in this situation.
In the present study, data from 1979 to 2002 (before the
current assay came into use) show that while a threshold of
>40 mU/L for capillary TSH was sensitive in predicting a low
fT4, speciﬁcity was much lower. By contrast, data from 2002 to
2013 using the AutoDELFIA assay give information of superior
predictive value, demonstrating that just over 90% of infants
who are found to have venous fT4 <10 pmol/L will have capil-
lary TSH values of ≥40 mU/L.
The infants with modest capillary TSH elevation (values
ranging between 8 and 40 mU/L) tended to be those requiring
repeat sampling rather than direct referral. Thus, over half of the
infants referred with capillary TSH values of ≤40 mU/L had been
referred after a second (or in four cases a third) capillary test.
Analysis of the current study suggests that if capillary TSH is
>40 mU/L, it is advisable to institute L-T4 treatment without
delay unless venous TFTs are available on the same day, since
the speciﬁcity of 66% for predicting a venous fT4 of 10 pmol/L
means that only 34% of such infants will have fT4 values of
≥10 pmol/L. By contrast, if capillary TSH is ≤40 mU/L and the
results of venous TFTs are not going to be available on the same
day, there is a case for deferring L-T4 treatment. This should
only be considered in situations when the infant is clinically
euthyroid and when venous blood results will be available
within a few days. The interval between the capillary TSH test
leading to referral (whether initial, ﬁrst or second repeat) should
also be taken into consideration.
An alternative approach is to ‘play safe’ and to always institute
L-T4 treatment in any infant with initial capillary TSH ≥25 mU/L
or repeat capillary TSH ≥8 mU/L in whom the venous blood
results are not immediately available. However, this strategy
deprives the clinician of being able to observe the venous TSH and
fT4 trends when the latter are within the reference range, may
adversely affect uptake on radioisotope scanning due to TSH sup-
pression13 and may commit the infant and family to 2 or 3 years
of potentially unnecessary treatment, followed by the need for
re-evaluation.7
We conclude that in situations where it is not feasible to
obtain the results of venous blood tests on the same day, those
infants with capillary TSH values of ≤40 mU/L who appear
clinically well with no symptoms or signs of hypothyroidism
(eg, jaundice, poor feeding, cold extremities) and in whom
blood results will be available shortly do not necessarily
require immediate treatment. However, immediate treatment is
advised when the infant is symptomatic irrespective of the
capillary TSH level.
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